SETD2 Antibodies Research Reagents

SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase, also known as LLS; HYPB; SET2; HIF-1; HIP-1; KMT3A; HBP231; HSPC069; p231HBP), located on 3p21.31, is a Protein Coding gene. The gene produces a 287597 Da protein composed of 2564 amino acids. SETD2 is the primary methyltransferase catalyzing H3K36 trimethylation (H3K36me3). SETD2 associates with the phosphorylated carboxy-terminal domain of RNA polymerase and modifies histones at actively transcribed genes. Diseases such as Luscan-Lumish Syndrome and Sotos Syndrome 1 are associated with SETD2.

SETD2 Antibody (1)

    SETD2 qPCR Primer (1)

    SETD2 の背景知識

    The SET domain-containing protein 2 (SETD2, also known as HYPB) is a 230-kD protein that is located at cytogenetic band p21.31 of chromosome 3. SETD2 is usually transformed or eradicated in multiple forms of tumors in humans and may play important roles in the active gene transcription in human cells. The H3 lysine 36 histone methyltransferase SETD2 is mutated across a range of human cancers. Although other enzymes can mediate mono- and dimethylation, SETD2 is the exclusive trimethylase. SETD2 associates with the phosphorylated carboxy-terminal domain of RNA polymerase and modifies histones at actively transcribed genes. The functions associated with SETD2 are mediated through multiple effector proteins that bind trimethylated H3K36. SETD2, the sole histone H3K36 trimethyltransferase, is frequently mutated or deleted in human cancer, including pancreatic ductal adenocarcinoma (PDAC).

    SETD2 の参考文献

    • Niu N, et al. (2020) Loss of setd2 promotes kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut 69 (4): 715-726.
    • Fahey CC, et al. (2017) Setting the stage for cancer development: Setd2 and the consequences of lost methylation. Cold Spring Harb Perspect Med 7 (5): a026468.
    • Diao YF, et al. (2018) Dynamic changes of setd2, a histone h3k36 methyltransferase, in porcine oocytes, ivf and scnt embryos. PLoS One 13 (2): e0191816.
    • Chen Z, et al. (2018) Setd2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion. Biochem Biophys Res Commun 498 (3): 579-585.

    Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.